Tags : Supply

Biotech

Pfizer Signs a License and Supply Agreement with ImaginAb for

Shots: ImaginAb to receive license fees and payments for manufacturing and other support and will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials ImaginAb will provide technical, clinical & regulatory support to Pfizer The collaboration follows the pre-competitive alliance b/w ImaginAb, Pfizer and other global companies […]Read More

Clinical Trials

Pfizer and BioNTech to Supply EU with up to 200M

Shots: The companies sign an agreement with the EC to supply 200M doses of BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to EU member states, with an option to request an additional 100M doses Deliveries are anticipated to start by the end of 2020, following clinical success and regulatory authorization. The companies expect to produce ~1.3B […]Read More

Pharma

IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid

Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer The two global companies have established JDC and there will be joint decision […]Read More

Biotech

BioNTech and Fosun Pharma to Supply ~10M Doses of COVID-19

Shots: BioNTech and Fosun collaborated to supply 10M doses of their BNT162 mRNA-based vaccine candidate against COVID-19 to Hong Kong SAR and Macao SAR, once approved Fosun Pharma has signed the Letter of Intent with Jacobson for contemplated distribution of 10M doses of a vaccine targeting COVID-19 in the Chinese market On Mar 13, 2020, […]Read More

Biosimilars

BeiGene Signs a License and Supply Agreement with Bio-Thera for

Shots: Bio-Thera to receive $165M upfront, regulatory, and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan while Bio-Thera will retain rights for the therapy outside the licensed territory The NMPA has […]Read More